
    
      This study will be conducted in two stages. Stage One is an open-label, adaptive
      dose-selection, safety and efficacy trial of up to four concentrations of DE-112 ophthalmic
      solution enrolling a total of 24 subjects.

      Stage Two of the study is a randomized, double-masked, placebo- and active-controlled,
      parallel-group, multi-center trial comparing the efficacy and safety of two concentrations of
      DE-112 ophthalmic solution with placebo and timolol enrolling a total of 120 subjects.
    
  